Global Pleurisy Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

Diagnosis devices play a crucial role in identifying and assessing pleurisy, aiding in accurate treatment planning and monitoring of patient progress. Thoracentesis, a common diagnostic procedure, involves the insertion of a needle into the pleural space to collect fluid for analysis. This allows healthcare professionals to determine the underlying cause of pleurisy, such as infection, inflammation, or malignancy. Video-Assisted Thoracic Surgery (VATS) provides a minimally invasive approach to visualize the pleura and obtain tissue samples for biopsy, aiding in definitive diagnosis and treatment planning. Imaging devices, including chest X-rays and CT scans, offer non-invasive methods for visualizing pleural abnormalities and assessing lung health. Blood tests, such as complete blood count (CBC) and inflammatory marker assays, provide additional diagnostic information, aiding in the identification of infection or inflammation.

Treatment options for pleurisy encompass a variety of pharmaceutical interventions tailored to address the underlying cause and alleviate symptoms. Antibiotics are commonly prescribed for pleurisy caused by bacterial infections, targeting the infectious agents and reducing inflammation. Antifungals are utilized in cases of fungal pleurisy, while blood thinners may be prescribed to prevent blood clots associated with pleural effusions. Nonsteroidal anti-inflammatory drugs (NSAIDs) provide relief from pain and inflammation associated with pleurisy, enhancing patient comfort and quality of life. Other treatment modalities, such as corticosteroids and immunosuppressive agents, may be utilized in cases of autoimmune-related pleurisy, providing targeted therapy to modulate the immune response.

End users of pleurisy diagnostics and treatments encompass a diverse array of healthcare facilities and providers involved in the care continuum. Hospitals serve as comprehensive centers for pleurisy diagnosis, treatment, and management, offering advanced diagnostic capabilities, specialized expertise, and acute care services. Clinics, including respiratory clinics and specialty practices, provide outpatient diagnostic and treatment services for individuals with pleurisy, offering convenient access to care and personalized treatment plans. Diagnostics laboratories play a critical role in analyzing pleural fluid samples and blood tests, providing timely and accurate diagnostic information to guide treatment decisions. Other end users, such as rehabilitation centers and home healthcare services, support patient recovery and management of chronic pleurisy, offering rehabilitative therapies and supportive care. Retail pharmacies play a vital role in dispensing medications prescribed for pleurisy treatment, ensuring patient access to essential pharmaceutical interventions.

Global Pleurisy Segment Analysis

In this report, the Global Pleurisy Market has been segmented by Diagnosis Devices, Treatment, End User and Geography.

Global Pleurisy Market, Segmentation by Diagnosis Devices

The Global Pleurisy Market has been segmented by Diagnosis Devices into Thoracentesis, Video-Assisted Thoracic Surgery, Imaging Devices, Blood Test and Others.

Thoracentesis stands as a cornerstone diagnostic procedure, involving the insertion of a needle into the pleural space to extract fluid for analysis. This procedure allows healthcare professionals to determine the composition of pleural fluid, aiding in the diagnosis of pleurisy and identification of underlying causes such as infections, inflammations, or malignancies. Thoracentesis serves as a valuable tool for obtaining diagnostic samples and guiding subsequent treatment decisions, contributing significantly to patient management and care.

Video-Assisted Thoracic Surgery (VATS) represents another essential diagnostic modality, offering a minimally invasive approach to visualize the pleural space and obtain tissue samples for biopsy. VATS allows for direct visualization of pleural abnormalities and facilitates the collection of tissue specimens, enabling definitive diagnosis and treatment planning. This advanced surgical technique is particularly valuable in cases where conventional diagnostic methods, such as thoracentesis or imaging, may be inconclusive or insufficient. VATS plays a crucial role in the diagnostic workup of pleurisy, providing clinicians with valuable insights into disease pathology and guiding subsequent therapeutic interventions.

Imaging devices, including chest X-rays and computed tomography (CT) scans, play a pivotal role in non-invasive pleurisy diagnosis, offering high-resolution images of the chest cavity and pleural space. These imaging modalities enable healthcare professionals to visualize pleural abnormalities, such as pleural effusions, pleural thickening, or pleural-based lesions, aiding in the differential diagnosis of pleurisy and other respiratory conditions. Chest X-rays provide a rapid and cost-effective means of evaluating pleural pathology, while CT scans offer enhanced sensitivity and specificity for detecting subtle pleural abnormalities. By providing detailed anatomical information, imaging devices contribute to accurate pleurisy diagnosis and inform subsequent treatment strategies.

Blood tests, including complete blood count (CBC) and inflammatory marker assays, serve as complementary diagnostic tools in the evaluation of pleurisy. CBC helps assess for signs of infection or inflammation, such as elevated white blood cell count, while inflammatory markers, such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR), provide valuable insights into the inflammatory response. These blood tests aid in the identification of underlying causes of pleurisy, such as bacterial or viral infections, autoimmune disorders, or malignancies, contributing to targeted treatment approaches and improved patient outcomes.

Global Pleurisy Market, Segmentation by Treatment

The Global Pleurisy Market has been segmented by Treatment into Antibiotics, Antifungals, Blood Thinners, Nonsteroidal Anti-Inflammatory Drugs and Others.

Antibiotics stand as a cornerstone of treatment for pleurisy caused by bacterial infections, such as pneumonia or pleural empyema. These antimicrobial agents target the infectious agents responsible for pleural inflammation, aiding in the resolution of infection and alleviation of symptoms. Antibiotic selection is guided by factors such as the suspected pathogen, antimicrobial susceptibility patterns, and patient-specific considerations, with the goal of achieving optimal clinical outcomes and minimizing the risk of treatment failure or antimicrobial resistance.

Antifungals represent another essential treatment modality for pleurisy attributed to fungal infections, such as pulmonary aspergillosis or fungal pleuritis. These antifungal agents target fungal pathogens responsible for pleural inflammation, facilitating the eradication of infection and restoration of pleural health. Antifungal therapy is tailored to the specific fungal species identified, with consideration given to factors such as antifungal susceptibility, disease severity, and patient characteristics, to optimize therapeutic efficacy and minimize the risk of treatment-related adverse events.

Blood thinners, or anticoagulants, play a vital role in the management of pleurisy associated with pulmonary embolism or pleural effusions secondary to venous thromboembolism. These pharmacological agents inhibit blood clot formation and promote fibrinolysis, reducing the risk of thromboembolic complications and facilitating the resolution of pleural effusions. Blood thinner selection is guided by factors such as the underlying thrombotic disorder, patient comorbidities, and bleeding risk, with the goal of achieving therapeutic anticoagulation while minimizing the risk of hemorrhagic complications.

Nonsteroidal anti-inflammatory drugs (NSAIDs) represent a mainstay of symptomatic treatment for pleurisy, providing analgesic and anti-inflammatory effects to alleviate chest pain and discomfort associated with pleural inflammation. These pharmacological agents inhibit prostaglandin synthesis and reduce inflammatory mediator release, leading to pain relief and improvement in pleural symptoms. NSAID selection is based on factors such as patient tolerance, comorbidities, and concurrent medications, with consideration given to the risk of gastrointestinal or cardiovascular adverse effects.

Other treatment modalities for pleurisy may include corticosteroids, immunosuppressive agents, or supportive therapies aimed at addressing underlying autoimmune disorders, inflammatory conditions, or malignancies contributing to pleural inflammation. These therapeutic interventions are tailored to the specific needs of individual patients, with consideration given to disease severity, treatment goals, and patient preferences, to optimize therapeutic outcomes and enhance quality of life.

Global Pleurisy Market, Segmentation by End User

The Global Pleurisy Market has been segmented by End User into Hospitals, Clinics, Diagnostics Laboratories, Others and Retail pharmacies.

Hospitals serve as comprehensive centers for pleurisy diagnosis, treatment, and management, offering a wide range of medical services and specialized expertise to address the complex needs of patients with pleurisy. These facilities provide advanced diagnostic capabilities, including thoracentesis, imaging studies, and laboratory testing, enabling accurate diagnosis and timely initiation of treatment. Hospitals also offer acute care services, such as intensive care units and surgical suites, for patients with severe pleurisy requiring intensive monitoring or invasive interventions.

Clinics, including respiratory clinics and specialty practices, represent another essential end user of pleurisy diagnostics and treatments, providing outpatient diagnostic and treatment services for individuals with pleurisy. These facilities offer convenient access to care and personalized treatment plans, catering to the diverse needs of patients with pleural inflammation. Clinics may specialize in respiratory medicine, pulmonary function testing, or thoracic surgery, offering specialized expertise and comprehensive care for patients with pleurisy and related respiratory conditions.

Diagnostics laboratories play a critical role in the evaluation of pleurisy, providing timely and accurate analysis of pleural fluid samples and blood tests to aid in diagnosis and treatment decision-making. These laboratories employ skilled technicians and utilize advanced laboratory techniques to perform cytological, microbiological, and biochemical analyses, generating valuable diagnostic information to guide patient management. Diagnostics laboratories collaborate closely with healthcare providers to ensure prompt and accurate reporting of test results, facilitating timely interventions and optimizing patient outcomes.

Other end users of pleurisy diagnostics and treatments may include rehabilitation centers, home healthcare services, and palliative care facilities, which support patient recovery and management of chronic pleurisy. Rehabilitation centers offer rehabilitative therapies, such as physical therapy and respiratory exercises, to improve lung function and enhance mobility in patients with pleural inflammation. Home healthcare services provide supportive care and monitoring for patients recovering from pleurisy or managing chronic symptoms at home. Palliative care facilities offer symptom management and supportive care for patients with advanced pleurisy, focusing on improving quality of life and alleviating suffering.

Retail pharmacies play a vital role in the distribution of medications prescribed for pleurisy treatment, ensuring patient access to essential pharmaceutical interventions. These facilities dispense antibiotics, antifungals, NSAIDs, and other medications prescribed by healthcare providers, providing counseling and support to patients regarding medication adherence, potential side effects, and drug interactions. Retail pharmacies play a crucial role in facilitating patient access to pleurisy medications and promoting medication safety and efficacy.

Global Pleurisy Market, Segmentation by Geography

In this report, the Global Pleurisy Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Pleurisy Market Share (%), by Geographical Region, 2024

North America represents a significant market for pleurisy diagnosis and treatment, driven by factors such as a large patient population, advanced healthcare infrastructure, and high healthcare expenditure. Countries like the United States and Canada boast well-established medical systems, specialized healthcare facilities, and a strong emphasis on research and development, contributing to the availability of advanced diagnostic modalities and therapeutic interventions for pleurisy. Additionally, increasing awareness of respiratory health and access to healthcare services further contribute to market growth in this region.

Europe is another prominent market for pleurisy diagnosis and treatment, encompassing countries like Germany, the United Kingdom, France, Italy, and Spain. The region benefits from robust healthcare systems, specialized medical expertise, and a growing emphasis on preventive care and early detection of respiratory conditions. Countries with advanced healthcare infrastructure, such as Germany and the United Kingdom, offer comprehensive diagnostic and treatment services for pleurisy, including advanced imaging modalities, minimally invasive procedures, and specialized respiratory care programs.

The Asia-Pacific region represents a rapidly growing market for pleurisy diagnosis and treatment, fueled by factors such as a large and aging population, rising healthcare expenditure, and increasing prevalence of respiratory conditions. Countries like China, Japan, India, and South Korea are witnessing significant investments in healthcare infrastructure, medical technology, and research, contributing to the expansion of pleurisy diagnostic capabilities and treatment options. Additionally, the presence of emerging economies with growing healthcare sectors, such as India and China, offers opportunities for market growth and expansion of pleurisy-related healthcare services.

Latin America represents an emerging market for pleurisy diagnosis and treatment, encompassing countries like Brazil, Mexico, Argentina, and Colombia. The region is characterized by improving healthcare infrastructure, rising disposable incomes, and increasing awareness of respiratory health issues. Countries like Brazil and Mexico boast specialized medical centers and research institutions focused on respiratory medicine, offering advanced diagnostic and treatment options for pleurisy. Additionally, initiatives aimed at improving access to healthcare services and reducing healthcare disparities contribute to market growth in this region.

The Middle East and Africa represent nascent markets for pleurisy diagnosis and treatment, characterized by improving healthcare infrastructure, expanding medical tourism, and increasing investments in healthcare technology and innovation. Countries like Saudi Arabia, UAE, South Africa, and Egypt are witnessing the development of specialized medical facilities and the adoption of advanced diagnostic and treatment modalities for respiratory conditions, including pleurisy. Additionally, initiatives aimed at enhancing healthcare access and quality contribute to market growth in this region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Pleurisy Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Drivers :

• Inflammation
• Respiratory Infections
• Autoimmune Disorders

• Malignancies - Malignancies, or cancerous growths, represent a significant concern within the context of pleurisy, as they can lead to inflammation of the pleura, the thin membrane that surrounds the lungs. Pleural malignancies can arise from primary tumors originating in the pleura itself, known as primary pleural tumors, or as secondary metastases from primary cancers elsewhere in the body, such as the lung, breast, or gastrointestinal tract.

  Primary pleural malignancies include malignant mesothelioma, a rare but aggressive cancer linked to asbestos exposure, as well as other less common tumors such as solitary fibrous tumors and primary pleural lymphomas. These cancers can cause inflammation of the pleura, resulting in symptoms such as chest pain, shortness of breath, and pleural effusions. Diagnosis typically involves imaging studies such as chest X-rays and CT scans, as well as tissue biopsy for histopathological examination.

  Metastatic pleural malignancies occur when cancer cells spread from primary tumors located in other organs to the pleura. Common primary sites for metastatic pleural tumors include the lungs, breast, prostate, and gastrointestinal tract. These metastases can infiltrate the pleura, leading to pleural thickening, nodularity, and effusions. Diagnosis involves identifying the primary tumor through imaging studies, laboratory tests, and histopathological analysis of pleural fluid or tissue samples obtained via thoracentesis or pleural biopsy.

  The management of pleural malignancies typically involves a multidisciplinary approach, with treatment options depending on factors such as tumor type, stage, and patient's overall health status. Treatment modalities may include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, either alone or in combination. Palliative care interventions, such as pleurodesis or pleural drainage, may also be employed to alleviate symptoms and improve quality of life for patients with advanced disease.

Restraints :

• Misdiagnosis
• Limited Treatment Options
• Side Effects of Medications

• High Treatment Costs - High treatment costs pose a significant challenge within the context of pleurisy management, impacting both patients and healthcare systems. Pleurisy treatment often involves a combination of diagnostic procedures, pharmacological interventions, and supportive care measures, each of which contributes to the overall cost burden for patients and healthcare providers.

  One of the primary contributors to high treatment costs is the extensive diagnostic workup required for pleurisy evaluation. Diagnostic procedures such as thoracentesis, imaging studies (e.g., chest X-rays, CT scans), and laboratory tests (e.g., pleural fluid analysis, blood tests) incur expenses related to equipment usage, consumables, and professional fees. Additionally, the need for specialized expertise in interpreting diagnostic results may further increase costs, particularly in cases requiring consultation with subspecialists or advanced imaging modalities.

  Pharmacological interventions for pleurisy, including antibiotics, antifungals, NSAIDs, and blood thinners, also contribute to treatment costs. The prices of medications can vary significantly depending on factors such as drug formulation, brand versus generic options, and availability. Moreover, the duration of treatment and potential need for combination therapies may further escalate medication expenses for patients, particularly those without adequate insurance coverage or access to subsidized healthcare services.

  In addition to diagnostic and pharmacological costs, supportive care measures such as hospitalization, surgical interventions, and rehabilitation services can substantially contribute to the overall cost burden associated with pleurisy treatment. Hospitalization costs, including room and board, nursing care, and ancillary services, can be particularly significant for patients with severe pleurisy requiring intensive monitoring or invasive procedures. Surgical interventions, such as VATS or pleurodesis, may entail additional expenses related to operating room fees, anesthesia services, and post-operative care.

Opportunities :

• Misdiagnosis
• Limited Treatment Options
• Side Effects of Medications

• High Treatment Costs - High treatment costs pose a formidable barrier to accessing effective care and can significantly impact both patients and healthcare systems within the context of pleurisy management. Pleurisy treatment encompasses a spectrum of interventions, including diagnostic procedures, pharmacological therapies, and supportive care measures, each contributing to the overall financial burden.

  Diagnostic procedures are often the initial step in pleurisy management, involving tests such as thoracentesis, imaging studies like chest X-rays or CT scans, and laboratory analyses of pleural fluid. These procedures require specialized equipment, skilled personnel, and sometimes, multiple rounds of testing for accurate diagnosis. The cumulative costs associated with diagnostic workups can escalate rapidly, especially if repeated evaluations are necessary to monitor disease progression or treatment response.

  Pharmacological therapies represent another significant cost component in pleurisy treatment. Antibiotics, antifungals, nonsteroidal anti-inflammatory drugs (NSAIDs), and other medications may be prescribed based on the underlying cause of pleurisy, such as infection or inflammation. However, the expense of these medications, particularly newer or patented drugs, can strain patients' finances, especially if they are required for an extended duration or if multiple medications are needed concurrently.

  The need for hospitalization and specialized interventions in severe cases of pleurisy further amplifies treatment costs. Hospital stays, surgical procedures (such as video-assisted thoracic surgery), and intensive care services entail substantial expenses related to facility fees, healthcare professionals' fees, medications, and ancillary services. Additionally, post-hospitalization rehabilitation or follow-up care may add to the financial burden, particularly for patients with prolonged recovery periods or ongoing medical needs.

Key players in Global Pleurisy Market include :

• Scanlan International, Inc.
• Sontec Instruments
• Pilling Surgical Inc.
• Integra LifeSciences Corporation
• Olympus Corporation
• Delacroix-Chevalier
• Myra & Co.
• Wexler Surgical
• Others

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis